Keryx Biopharms Drug Patent Portfolio
Keryx Biopharms owns 1 orange book drug protected by 15 US patents Given below is the list of Keryx Biopharms's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10300039 | Ferric citrate dosage forms | 21 Jul, 2030 | Active |
US9387191 | Ferric citrate dosage forms | 21 Jul, 2030 | Active |
US8093423 | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same | 21 Apr, 2026 | Active |
US7767851 | Ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US8299298 | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same | 18 Feb, 2024 | Expired |
US8338642 | Ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US8609896 | Ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US8754257 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US8754258 | Ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US8846976 | Ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US8901349 | Ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US9050316 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US9328133 | Ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US9757416 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same | 18 Feb, 2024 | Expired |
US5753706 | Methods for treating renal failure | 03 Feb, 2022 | Expired |
Latest Legal Activities on Keryx Biopharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Keryx Biopharms.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 17 Apr, 2024 | US8299298 |
Payment of Maintenance Fee, 8th Year, Large Entity | 27 Dec, 2023 | US9387191 |
Payment of Maintenance Fee, 12th Year, Large Entity | 28 Jun, 2023 | US8093423 |
Payment of Maintenance Fee, 4th Year, Large Entity | 11 Nov, 2022 | US10300039 |
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 09 Nov, 2022 | US10300039 |
Payment of Maintenance Fee, 8th Year, Large Entity | 09 Nov, 2022 | US9050316 |
Payment of Maintenance Fee, 8th Year, Large Entity | 09 Mar, 2022 | US8846976 |
Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jan, 2022 | US7767851 |
Payment of Maintenance Fee, 8th Year, Large Entity | 11 Nov, 2021 | US8754257 |
Payment of Maintenance Fee, 8th Year, Large Entity | 11 Nov, 2021 | US8754258 |
Payment of Maintenance Fee, 8th Year, Large Entity | 13 May, 2021 | US8609896 |
Payment of Maintenance Fee, 4th Year, Large Entity | 11 Feb, 2021 | US9757416 |
Payment of Maintenance Fee, 8th Year, Large Entity | 20 May, 2020 | US8338642 |
Payment of Maintenance Fee, 8th Year, Large Entity | 25 Mar, 2020 | US8299298 |
Payment of Maintenance Fee, 4th Year, Large Entity | 08 Jan, 2020 | US9387191 |
Keryx Biopharms Drug Patents' Oppositions Filed in EPO
Keryx Biopharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 25, 2015, by Hexal Ag. This opposition was filed on patent number EP06813544A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP07717051A | Dec, 2016 | Hexal AG | Opposition rejected |
EP06813544A | Nov, 2015 | Hexal AG | Revoked |
Keryx Biopharms's Family Patents
Keryx Biopharms Drug List
Given below is the complete list of Keryx Biopharms's drugs and the patents protecting them.
1. Auryxia
Auryxia is protected by 15 patents, out of which 12 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10300039 | Ferric citrate dosage forms |
21 Jul, 2030
(5 years from now)
| Active |
US9387191 | Ferric citrate dosage forms |
21 Jul, 2030
(5 years from now)
| Active |
US8093423 | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
21 Apr, 2026
(1 year, 3 months from now)
| Active |
US7767851 | Ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US8299298 | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US8338642 | Ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US8609896 | Ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US8754257 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US8754258 | Ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US8846976 | Ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US8901349 | Ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US9050316 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US9328133 | Ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US9757416 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
18 Feb, 2024
(10 months ago)
| Expired |
US5753706 | Methods for treating renal failure |
03 Feb, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Auryxia's drug page